The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.

Merck & Co. is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer ...

Merck said on Monday it would create a separate division for its cancer business, anchored by its top-selling drug Keytruda, as the U.S. drugmaker braces for the upcoming patent expiry of the ...

Merck is splitting its pharmaceutical business into two units, separating its oncology operations from its non-cancer drugs as it prepares for the 2028 US patent expiry of its blockbuster cancer drug ...

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its ...

Merck’s decision to establish oncology as a standalone business unit is easy to describe and tempting to oversimplify. At ...

Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.

The drugmaker is reorganizing to bolster product launches ahead its cancer drug Keytruda’s patent loss.

Investors gave a collective meh to news that Merck & Co Inc (NYSE:MRK, XETRA:6MK) is reportedly restructuring its human-health division, with shares marking time in premarket trading despite a ...

Merck (MRK) announced plans to separate its core pharmaceutical division into two units as it prepares for the upcoming patent expiration of its top-selling drug. The drugmaker said it is organizing ...

Merck has an attractive yield and a long history of dividend growth.